These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 7814829)

  • 1. The importance of accidents in evaluating the cost of SSRIs: a review.
    Hale AS
    Int Clin Psychopharmacol; 1994 Sep; 9(3):195-201. PubMed ID: 7814829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are SSRIs a cost-effective alternative to tricyclics?
    Hotopf M; Lewis G; Normand C
    Br J Psychiatry; 1996 Apr; 168(4):404-9. PubMed ID: 8730935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The behavioural toxicity of the selective serotonin reuptake inhibitors.
    Hindmarch I
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():13-7. PubMed ID: 7622818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SSRIs vs tricyclic antidepressants.
    Griffin GH
    J Fam Pract; 1996 Feb; 42(2):110. PubMed ID: 8606296
    [No Abstract]   [Full Text] [Related]  

  • 5. One foot on the bandwagon?
    Pies R
    J Clin Psychopharmacol; 1995 Oct; 15(5):303-5. PubMed ID: 8830060
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-benefit analysis of newer versus older antidepressants--pharmacoeconomic studies comparing SSRIs/SNRIs with tricyclic antidepressants.
    Laux G
    Pharmacopsychiatry; 2001 Jan; 34(1):1-5. PubMed ID: 11229615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SSRIs versus tricyclics.
    Rubinsztien JS; Michael A
    Br J Psychiatry; 1996 Jul; 169(1):113-4. PubMed ID: 8818380
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
    Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
    Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial.
    Kendrick T; Peveler R; Longworth L; Baldwin D; Moore M; Chatwin J; Thornett A; Goddard J; Campbell M; Smith H; Buxton M; Thompson C
    Br J Psychiatry; 2006 Apr; 188():337-45. PubMed ID: 16582060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influences on cost effectiveness.
    Patel V
    Br J Psychiatry; 1996 Sep; 169(3):381. PubMed ID: 8879730
    [No Abstract]   [Full Text] [Related]  

  • 11. An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.
    Berndt ER; Bhattacharjya A; Mishol DN; Arcelus A; Lasky T
    J Ment Health Policy Econ; 2002 Mar; 5(1):3-19. PubMed ID: 12529566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression.
    Crown WH
    Acta Psychiatr Scand Suppl; 2000; 403():62-6. PubMed ID: 11019937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis.
    Anderson IM; Tomenson BM
    BMJ; 1995 Jun; 310(6992):1433-8. PubMed ID: 7613276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of antidepressant choice on the incidence and economic intensity of hospitalization among depressed individuals.
    Croghan TW; Kniesner TJ; Melfi CA; Robinson RL
    Adm Policy Ment Health; 2000 Mar; 27(4):183-95. PubMed ID: 10911668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCAs or SSRIs as initial therapy for depression?
    Tyra JM; Greenawald MH
    J Fam Pract; 1999 Nov; 48(11):845-6. PubMed ID: 10907616
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacological treatment of depression with and without headache disorders: an appraisal of cost effectiveness and cost utility of antidepressants.
    Pan YJ; Kuo KH; Wang SJ
    J Affect Disord; 2015 Jan; 170():255-65. PubMed ID: 25261631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sertraline. A pharmacoeconomic evaluation of its use in depression.
    Davis R; Wilde MI
    Pharmacoeconomics; 1996 Oct; 10(4):409-31. PubMed ID: 10184609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of severe depression with the selective serotonin reuptake inhibitors.
    Schatzberg AF
    Depress Anxiety; 1996-1997; 4(4):182-9. PubMed ID: 9166650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity.
    Hotopf M; Hardy R; Lewis G
    Br J Psychiatry; 1997 Feb; 170():120-7. PubMed ID: 9093499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses.
    Taylor D
    Br J Psychiatry; 1995 Nov; 167(5):575-80. PubMed ID: 8564311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.